Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 13Dermatologic 7Thoracic 3Other hematologic neoplasm 3Genitourinary 3Gastrointestinal 3Breast 3Sarcoma 2Plasma cell 2Other solid neoplasm 2CNS 2Tumor-Agnostic 1NET 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 870Lenalidomide 456Bortezomib 454Cyclophosphamide 365Melphalan 271Calcium Dobesilate 262daratumumab 233pomalidomide 207carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74Cyclosporine 68isatuximab 67auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 56Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Depsipeptides × Plasma cell × Clear all
NCT00765102 2019-11-25

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Celgene

Phase 2 Terminated
32 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT00431990 2011-08-12

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Unknown
40 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡